Raltegravir During Pregnancy
A study of the pharmacokinetics of raltegravir use during pregnancy showed that the medication, when taken twice daily as part of cART, readily crossed the placenta however the median raltegravir area under the curve was reduced by approximately 50% during pregnancy. Despite this fact, viral suppression rates indicate that a higher dose is not necessary during pregnancy.
Citation:
Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, and Mirochnick M for the IMPAACT 1026s study team. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2104 Dec 1;67(4):375-81.
Original Article (subscription may be required)
